千金药业 发行股份及支付现金购买资产暨关联交易报告书 证券代码：600479 证券简称：千金药业 上市地点：上海证券交易所 株洲千金药业股份有限公司 发行股份及支付现金购买资产 暨关联交易报告书 | 项目 | 交易对方 | | --- | --- | | 发行股份及 | 株洲市国有资产投资控股集团有限公司、淮安市列邦康泰化工有限公司、黄 | | | 阳、汤振军、汤曜铭、唐闻伯、邓汝腾、叶胜利、刘金玉、周莉华、金亮、 | | 支付现金购 | | | | 钟林波、张新民、彭华军、王洪锋、雷颖、丁四海、刘军明、陈积安、罗斌、 | | 买资产 | | | | 殷文新、吴永强、彭彩霞 | 独立财务顾问 签署日期：二〇二五年九月 千金药业 发行股份及支付现金购买资产暨关联交易报告书 上市公司声明 本公司及全体董事、监事、高级管理人员保证本报告书及其摘要内容的真实、 准确、完整，对报告书的虚假记载、误导性陈述或重大遗漏负相应的法律责任。 本公司控股股东、董事、监事、高级管理人员声明：如本次交易所披露或提 供的信息涉嫌虚假记载、误导性陈述或者重大遗漏，被司法机关立案侦查或者被 中国证监会立案调查的，在形成调查结论以前，不转让 ...

公司于 2025 年 8 月 30 日披露了《株洲千金药业股份有限公司发行股份及支 付现金购买资产暨关联交易报告书（草案）（注册稿）》等文件。具体内容详见公 司刊登在上海证券交易所网站（http://www.sse.com.cn）的相关文件。 公司于 2025 年 9 月 12 日收到中国证券监督管理委员会出具的《关于同意株 洲千金药业股份有限公司发行股份购买资产注册的批复》（证监许可〔2025〕2002 号）。 相较公司于 2025 年 8 月 30 日披露的《株洲千金药业股份有限公司发行股份 及支付现金购买资产暨关联交易报告书（草案）（注册稿）》，本次披露的重组报 告书对部分内容进行了更新和修订，主要情况如下： | 报告书章节 | | 修订情况 | | --- | --- | --- | | 重大事项提示 | | 更新了本次交易已履行及尚需履行的程序 | | 重大风险提示 | | 删除了本次交易的相关审批风险 | | 第一节 | 本次交易概况 | 更新了本次交易已履行及尚需履行的程序 | | 第十二节 | 风险因素 | 删除了本次交易的相关审批风险 | 注：本说明所述词语或简称与报告书"释义"所述词语或简 ...

Core Viewpoint - The company, Zhuzhou Qianjin Pharmaceutical Co., Ltd., is proceeding with the acquisition of stakes in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment, following the approval from the China Securities Regulatory Commission [1][2]. Group 1: Transaction Implementation - The transfer of ownership for the targeted assets has been completed, with the company acquiring 28.92% of Qianjin Xiangjiang Pharmaceutical and 68.00% of Qianjin Xieli Pharmaceutical [2]. - The involved parties, including Zhuzhou State-owned Assets Investment Holding Group Co., Ltd. and other individuals, have successfully transferred their shares to the company [2]. Group 2: Subsequent Matters - The company is required to issue shares and make cash payments to the relevant parties as per the transaction agreement, and must also handle the registration and listing of the newly issued shares [3]. - Changes related to the increase in registered capital and amendments to the company’s articles of association must be filed with the relevant regulatory authorities [3]. - The company must continue to fulfill its information disclosure obligations regarding the transaction as per legal and regulatory requirements [3]. Group 3: Independent Advisors' Opinions - The independent financial advisor, Guotou Securities Co., Ltd., confirmed that the transaction followed necessary decision-making and approval processes, and that the transfer of assets was legally valid [4][5]. - The legal advisor, Hunan Qiyuan Law Firm, stated that the transaction complies with legal regulations and that all necessary approvals have been obtained, ensuring that the company legally holds the assets [5].

湖南启元律师事务所 关于 株洲千金药业股份有限公司 发行股份及支付现金购买资产暨关联交易之 标的资产过户情况的 法律意见书 二〇二五年九月 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 电话：0731-82953778 传真：0731-82953779 邮编：410000 网站：www.qiyuan.com 根据千金药业第十一届董事会第九次会议、第十一届董事会第十一次会议、 2025 年第一次临时股东大会审议通过的与本次交易相关的各项议案、千金药业与交 易对方签署的《发行股份购买资产协议》《发行股份及支付现金购买资产协议》等 与本次交易相关的文件，本次交易方案的主要内容如下： 本次交易为上市公司收购控股子公司少数股东权益。上市公司拟通过发行股份 的方式购买株洲国投及列邦康泰持有的千金湘江药业合计 28.92%的股权；拟通过发 行股份的方式购买株洲国投及黄阳等 20 名自然人持有的千金协力药业 67.06%的股权、 拟通过支付现金的方式购买钟林波持有的千金协力药业 0.94%的股权，合计购买千金 协力药业 68%的股权。 致：株洲千金药业股份有限公司 湖南启元律师事务所（以下简称"本所"）接受 ...

国投证券股份有限公司 关于 株洲千金药业股份有限公司发行股份及支付现金购 买资产暨关联交易 之标的资产过户情况的 独立财务顾问核查意见 独立财务顾问 二〇二五年九月 声明和承诺 国投证券股份有限公司（以下简称"本独立财务顾问"）受株洲千金药业股 份有限公司（以下简称"千金药业""上市公司"或"公司"）委托，担任其本次 发行股份及支付现金购买资产暨关联交易的独立财务顾问。 本独立财务顾问核查意见是根据《中华人民共和国公司法》《中华人民共和 国证券法》《上市公司重大资产重组管理办法》《上市公司并购重组财务顾问业务 管理办法》《公开发行证券的公司信息披露内容与格式准则第 26 号——上市公司 重大资产重组》等相关法律法规的规定，按照证券行业公认的业务标准、道德规 范，本着诚实信用、勤勉尽责的精神，遵循客观、公正原则，在认真审阅相关资 料和充分了解本次交易行为的基础上，本独立财务顾问出具了就上市公司本次资 产重组相关资产交割过户情况的核查意见，本独立财务顾问对本核查意见特作如 下声明： 1、本独立财务顾问核查意见所依据的文件和材料由本次交易各方提供，提 供方对所提供文件及资料的真实性、准确性和完整性负责，并保证该等信 ...

证券代码：600479 证券简称：千金药业 公告编号：2025-048 一、本次交易的实施情况 （一）标的资产交割过户 截至本公告日，株洲国有资产投资控股集团有限公司（以下简称"株洲国投"）、 淮安列邦康泰化工有限公司（以下简称"列邦康泰"）合计持有的千金湘江药业 28.92%的股权以及株洲国投和黄阳等 21 名自然人合计持有的千金协力药业 68.00%的股权已过户至公司名下，本次交易涉及的标的资产交割过户手续已办理 完毕，公司已合法取得标的资产。 株洲千金药业股份有限公司 关于发行股份及支付现金购买资产暨关联交易之标的资产 过户情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 株洲千金药业股份有限公司（以下简称"公司"）拟通过发行股份及支付现 金方式购买湖南千金湘江药业股份有限公司 28.92%的股权及湖南千金协力药业 有限公司 68.00%的股权（以下简称"本次交易"）。 公司于 2025 年 9 月 12 日收到中国证券监督管理委员会出具的《关于同意株 洲千金药业股份有限公司发行股份购买资产注册的批复》（ ...

Group 1 - Baiyang Pharmaceutical plans to strategically invest in Jikun Pharmaceutical by acquiring a 24% stake, securing rights to the innovative drug for pulmonary fibrosis, JK1033, and gaining priority purchase rights for all global compound rights of Jikun Pharmaceutical's products [1] - Qianjin Pharmaceutical received approval from the China Securities Regulatory Commission to issue shares and purchase stakes in Hunan Qianjin Xiangjiang Pharmaceutical (28.92%) and Hunan Qianjin Xieli (68%), enhancing its collaboration in the western medicine sector and supporting its "one main, two auxiliary" strategy [2] - BGI Genomics' major shareholder, Shenzhen BGI Genomics Technology Co., plans to transfer 4% of its shares (16.73 million shares) through a pricing inquiry to meet funding needs for cutting-edge technology incubation in cell and spatiotemporal genomics [3] Group 2 - Suoyuan Biotech's key ENLIGHTEN trial results were published in the prestigious journal JAMA Psychiatry, showing significant efficacy of DB104 (Liafensine) in treatment-resistant depression patients with the ANK3 biomarker, marking a breakthrough in precision medicine for mental health [4] - Betta Pharmaceuticals intends to list on the Hong Kong Stock Exchange, reporting a revenue of 1.731 billion yuan in the first half of 2025, a 15.37% increase, but a net profit decline of 37.53% to 140 million yuan, indicating challenges despite growth in revenue [5]

Group 1 - Zhuzhou Qianjin Pharmaceutical Co., Ltd. received approval from the China Securities Regulatory Commission to acquire 28.92% of Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68.00% of Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment [1] - The transaction aims to enhance the control of Zhuzhou Guotou over the listed company, increasing its shareholding from 28.76% to 34.94%, which supports stable governance and control of the listed company [1] - The effects of policies such as the "Eight Articles for the Sci-Tech Innovation Board" and "Six Articles for Mergers and Acquisitions" are becoming evident, with 27 merger and reorganization projects accepted and 15 approved by the review committee since 2025, surpassing last year's total [1] Group 2 - The Shanghai Stock Exchange is focused on improving the efficiency of reorganization reviews, with several innovative and exemplary merger and reorganization cases being implemented, such as the mergers involving Silyus and Sanyou Medical [2] - Notable cases include the acquisition of Chiplink Integrated by Chiplink Yuezhou, the largest merger project in A-shares involving China Shipbuilding and China Shipbuilding Heavy Industry, and cross-industry mergers by Songfa Co. and cross-border mergers by Zhizheng Co. [2]

Group 1 - The stock price of Qianjin Pharmaceutical (600479) closed at 10.96 yuan on September 12, 2025, up 0.37% from the previous week [1] - The company's total market capitalization is 4.625 billion yuan, ranking 45th out of 67 in the traditional Chinese medicine sector and 3516th out of 5153 in the A-share market [1] - The highest intraday price reached 11.23 yuan and the lowest was 10.85 yuan on September 11, 2025 [1] Group 2 - Qianjin Pharmaceutical received approval from the China Securities Regulatory Commission (CSRC) for the issuance of shares to acquire assets, specifically 28.92% equity in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68.00% equity in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. [2] - The approval is valid for 12 months from the date of issuance, and the company must comply with the application documents submitted to the Shanghai Stock Exchange [2] - The company is required to fulfill information disclosure obligations and report any significant issues during the implementation process [2] Group 3 - The financial advisor, Guotai Junan Securities Co., Ltd., provided a continuous supervision opinion on the acquisition report, confirming that the acquirer and its concerted parties have complied with regulations [1][3] - There are no major adjustments planned for the acquirer's main business, asset restructuring, board or executive changes, employee hiring, dividend policies, or other significant plans during the supervision period [1][3]

Core Viewpoint - The company plans to acquire a total of 28.92% equity in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68% equity in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment [1] Group 1 - The company announced on September 12 that it received approval from the China Securities Regulatory Commission (CSRC) for the asset acquisition [1] - The CSRC has agreed to allow the company to issue 51.4449 million shares to specific investors for the acquisition of the related assets [1] - The share issuance and asset acquisition must comply with the application documents submitted to the Shanghai Stock Exchange and must be completed within 12 months [1]